文献速递心力衰竭与心肌病

无导线超声心脏再同步化系统在心力衰竭中的应用

Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure.
PubMed 文献 · JAMA Cardiol · 2024-01-01

SOLVE-CRT 研究评估无导线左室心内膜起搏系统(WiSE CRT)用于常规 CRT 升级高风险或冠状窦导线放置/起搏失败患者的安全性和有效性。

要点

  • WiSE CRT 系统可使高危或常规 CRT 失败患者 LVESV 平均降低 16.4%。
  • 无 I 型并发症率为 80.9%,其中心脏穿孔多发生于研究早期。
  • 该无导线系统可能成为部分心衰患者传统 CRT 植入的替代方案。

核心结论

  • 无导线左室心内膜起搏(WiSE CRT 系统)与心衰患者 LVESV 降低相关,可能成为部分心衰人群传统 CRT 植入的替代选择。

研究设计与样本

  • SOLVE-CRT 为前瞻性多中心试验,2018 年 1 月至 2022 年 7 月入组,随访 6 个月,数据截至 2023 年 2 月 15 日分析。
  • 试验合并初始随机双盲研究(n=108)与后续单臂部分(n=75),在澳大利亚、欧洲和美国的 36 个中心开展。
  • 纳入非反应者、既往无法治疗(PU)或高风险升级(HRU)患者;安全性分析纳入全部 183 例,主要疗效分析纳入 100 例(单臂部分 75 例 PU-HRU 及随机治疗臂 25 例 PU-HRU)。
  • 干预为 WiSE CRT 系统(EBR Systems),由无导线左室心内膜起搏电极、皮下植入的超声发射器和电池组成。

主要发现

  • 共纳入 183 例,平均年龄 68.1(SD 10.3)岁,男性 141 例(77%)。
  • 试验因中期分析达到预设停止标准而终止。
  • 安全性人群中 NYHA II 级占 34.6%,III 级占 65.4%。

临床怎么用

  • 对于常规 CRT 升级高风险或冠状窦导线放置/起搏失败的心衰患者,可考虑无导线左室心内膜起搏作为替代方案。
  • 应用时需关注 I 型并发症,其中心脏穿孔多发生于研究早期,提示学习曲线或操作经验的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Approximately 40% of patients with heart failure (HF) who are eligible for cardiac resynchronization therapy (CRT) either fail to respond or are untreatable due to anatomical constraints. OBJECTIVE: To assess the safety and efficacy of a novel, leadless, left ventricular (LV) endocardial pacing system for patients at high risk for a CRT upgrade or whose coronary sinus (CS) lead placement/pacing with a conventional CRT system failed. DESIGN, SETTING, AND PARTICIPANTS: The SOLVE-CRT study was a prospective multicenter trial enrolling January 2018 through July 2022, with follow-up at 6 months. Data were analyzed from January 17, 2018, through February 15, 2023. The trial combined data from an initial randomized, double-blind study (n = 108) and a subsequent single-arm part (n = 75). It took place at 36 centers across Australia, Europe, and the US. Participants were nonresponders, previously untreatable (PU), or high-risk upgrades (HRU). All participants contributed to the safety analysis. The primary efficacy analysis (n = 100) included 75 PU-HRU patients from the single-arm part and 25 PU-HRU patients from the randomized treatment arm. INTERVENTIONS: Patients were implanted with the WiSE CRT System (EBR Systems) consisting of a leadless LV endocardial pacing electrode stimulated with ultrasound energy delivered by a subcutaneously implanted transmitter and battery. MAIN OUTCOMES AND MEASURES: The primary safety end point was freedom from type I complications. The primary efficacy end point was a reduction in mean LV end systolic volume (LVESV). RESULTS: The study included 183 participants; mean age was 68.1 (SD, 10.3) years and 141 were male (77%). The trial was terminated at an interim analysis for meeting prespecified stopping criteria. In the safety population, patients were either New York Heart Association Class II (34.6%) or III (65.4%). The primary efficacy end point was met with a 16.4% (95% CI, -21.0% to -11.7%) reduction in mean LVESV (P = .003). The primary safety end point was met with an 80.9% rate of freedom from type I complications (P < .001), which included 12 study device system events (6.6%), 5 vascular events (2.7%), 3 strokes (1.6%), and 7 cardiac perforations which mostly occurred early in the study (3.8%). CONCLUSIONS AND RELEVANCE: The SOLVE-CRT study has demonstrated that leadless LV endocardial pacing with the WiSE CRT system is associated with a reduction in LVESV in patients with HF. This novel system may represent an alternative to conventional CRT implants in some HF patient populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT0292203.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Singh, Rinaldi, Sanders, et al. Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure. JAMA Cardiol. 2024. PMID: 39083254. doi:10.1001/jamacardio.2024.2050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。